Cantor Fitzgerald’s Aurinia Pharmaceuticals AUPH Stock Holding History

Cantor Fitzgerald’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-68,196	Closed	-$754K	–	228
2025 Q3	$754K	Hold	68,196	–	–	0.01%	248
2025 Q2	$578K	Buy	+68,196	New	+$547K	0.01%	214
2025 Q1	–	Sell	-72,000	Closed	-$647K	–	330
2024 Q4	$647K	Buy	+72,000	New	+$587K	0.01%	107
2024 Q2	–	Sell	-54,033	Closed	-$271K	–	263
2024 Q1	$271K	Sell	54,033 -91,277	-63%	-$619K	0.06%	128
2023 Q4	$1.31M	Buy	145,310 +44,855	+45%	+$369K	0.27%	52
2023 Q3	$781K	Buy	100,455 +26,799	+36%	+$262K	0.02%	293
2023 Q2	$713K	Sell	73,656 -3,077	-4%	-$31.9K	0.02%	332
2023 Q1	$841K	Buy	76,733 +24,780	+48%	+$218K	0.02%	387
2022 Q4	$224K	Sell	51,953 -99,690	-66%	-$578K	﹤0.01%	557
2022 Q3	$1.14M	Sell	151,643 -15,580	-9%	-$135K	0.02%	409
2022 Q2	$1.68M	Buy	+167,223	New	+$1.87M	0.03%	391

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cantor Fitzgerald's AUPH Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 68,196 shares — an estimated $754K sold.

Cantor Fitzgerald first reported a position in AUPH in Q2 2022 and held it in 11 quarters. The position peaked at $1.68M in Q2 2022. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

Cantor Fitzgerald reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Cantor Fitzgerald sold 68,196 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $754K.
Cantor Fitzgerald first reported a position in Aurinia Pharmaceuticals in Q2 2022 and held it in 11 quarters.
Cantor Fitzgerald's Aurinia Pharmaceuticals position peaked at $1.68M in Q2 2022.
255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.